RxDoctor Payments Data

Melissa Coefield

Family · Lineville, ALNPI 1497911903

Payments from drug & device makers

$430in general payments, 2019–2025

Across 12 payments — averaging $35.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$186
  • Welch Allyn$107
  • Novo Nordisk$37
  • Galt Pharmaceuticals, LLC$36
  • Boehringer Ingelheim$31
  • AbbVie$18
  • plus $16 from 2 others

What the payments were for

  • Food & beverage$32375%
  • Other$10725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC3$186
Welch Allyn1$107
Novo Nordisk2$37
Galt Pharmaceuticals, LLC1$36
Boehringer Ingelheim2$31
AbbVie1$18
Exact Sciences1$14
Genentech USA, Inc.1$2

How this compares

$430 in reported general payments places this provider in the 50th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$51,963
Medicare patients
247
Services billed
3,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$46,394
OzempicSemaglutide14$14,454
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,586
Doxycycline Monohydrate110$1,288
Levothyroxine Sodium60$1,086
Bupropion Hcl21$728
Albuterol Sulfate HfaAlbuterol Sulfate31$693
Pantoprazole Sodium20$610
Atorvastatin Calcium55$610
Fluconazole29$494
Azithromycin90$437
Montelukast Sodium31$424
Carvedilol42$419
Duloxetine Hcl13$388
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst38$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$186$46,39446 claims
Novo NordiskOzempic$37$14,45414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,415 family providers in Alabama.

Other family in Lineville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →